Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ENTX
STRONG SELLEntera Bio Ltd. · Healthcare · Israel · $101M · Avg Vol: $10M/d
COMPANY DESCRIPTION
Entera Bio Ltd. is an Israeli clinical-stage biotechnology company specializing in the development of orally administered peptide and protein therapeutics. The company's competitive advantage is its proprietary oral delivery platform, which overcomes the biological barriers of the gastrointestinal tract to deliver large molecules that traditionally require injection. Entera operates as a pioneer in oral peptide delivery, targeting major therapeutic areas such as osteoporosis and hypoparathyroidism with patient-friendly oral alternatives.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.1M | 0 | 0.2M | 42.0K | -32.1% | — | — | — | — |
| EPS | -0.45 | -0.31 | -0.25 | -0.25 | — | -0.26 | -0.34 | -0.57 | — |
| Shares | 28.8M | 35.5M | 38.8M | 46.2M | +60.3% | 49.3M | — | — | — |
| Debt | 91.0K | 0.4M | 0.3M | 0.5M | 75.3% | 0.4M | — | — | — |
| Equity | 11.8M | 10.4M | 8.1M | 13.1M | 3.7% | — | — | — | — |
| Op CF | -12.5M | -7.3M | -6.8M | -7.4M | — | -10.9M | — | — | — |
| Inv CF | -0.1M | -17.0K | -3.0K | -0.1M | — | — | — | — | — |
| Fin CF | 13.0K | 6.0M | 4.5M | 13.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ENTX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ENTX | Entera Bio Ltd.(you) | $101M | 17 | STRONG SELL |
| PYPD | PolyPid Ltd. | $75M | 21 | SELL |
| ENLV | Enlivex Ltd. | $71M | 12 | STRONG SELL |
| MDWD | MediWound Ltd. | $183M | 8 | STRONG SELL |
| SLGL | Sol-Gel Technologies Ltd. | $268M | 33 | SELL |
| DRTS | Alpha Tau Medical Ltd. | $1.1B | 26 | SELL |
| CGEN | Compugen Ltd. | $216M | 98 | STRONG BUY |
| NNOX | Nano-X Imaging Ltd. | $62M | 8 | STRONG SELL |
| INCR | InterCure Ltd. | $55M | 36 | HOLD |
| BVC.L | BATM Advanced Communications Ltd. | $67M | 51 | HOLD |
Peer medians: ROE 5.1% · P/E 16.5x · Gross margin 36.8%